Redefining functional high‐risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation

Cancer 2026 Open access

Read full text
Authors: Gayathri Ravi, Binod Dhakal, Natalie S. Callander, Eva Medvedova, Bhagirathbhai Dholaria, Kelly Nicole Godby, Susan Bal, Forest Huls, Rebecca Wang Silbermann, Luciano J. Costa
DOI: 10.1002/cncr.70478
Cited by: 1
References: 18

Abstract

BACKGROUND: Functional high-risk (FHR) multiple myeloma (MM) was historically defined as progression within 18 months of starting therapy, with expected subsequent overall survival (OS)

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Cancer Treatment and Pharmacology Hematopoietic Stem Cell Transplantation

Publication details

Journal / source
Cancer
Publisher
Wiley
Volume
132
Issue
14
Pages
e70478–e70478
Publication date
15 July 2026
Language
EN